Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced Fc receptor binding

A technology of multimerization and composition, applied in the fields of autoimmunity, inflammation and tumor immunology, and immunology, which can solve problems such as the ability of unclear molecules to bind to FcγR or complement proteins.

Inactive Publication Date: 2019-04-16
GLIKNIK
View PDF28 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, given the complexities presented between affinity and affinity interactions, it is unclear how the point mutations described in the literature, many of which alter the affinity of a given mAb, would affect molecules composed of polyFc Ability to bind FcγRs or complement proteins

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced Fc receptor binding
  • Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced Fc receptor binding
  • Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced Fc receptor binding

Examples

Experimental program
Comparison scheme
Effect test

specific example

[0220]Oral or sublingual dissolvable tablet: Angina, polyarteritis nodosa.

[0221] Intravenous, intramuscular, or subcutaneous: myasthenia gravis, hemolytic uremic syndrome (HUS), atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), membranous nephropathy, Neuromyelitis optica, antibody-mediated allograft rejection, lupus nephritis, membranous proliferative glomerulonephritis (MPGN), idiopathic thrombocytopenic purpura, inclusion body myositis, paraproteinaemic IgM decapitation Myelinating polyneuropathy, necrotizing fasciitis, pemphigus, gangrene, dermatomyositis, granuloma, lymphoma, sepsis, aplastic anemia, multisystem organ failure, multiple myeloma of undetermined significance, and Clonal gammopathy, chronic inflammatory demyelinating polyradiculoneuropathy, inflammatory myopathy, thrombotic thrombocytopenic purpura, myositis, anemia, neoplasia, hemolytic anemia, encephalitis, myelitis, spinal cord disease (particularly associated with h...

example 1

[0264] Example 1: Common Storado body

[0265] Various methods were employed to generate Storaolibodies with enhanced classical binding and enhanced complement fixation. Trimers were generated in which at least one point mutation was introduced into the Fc domain. Specifically, the 233rd, 234th, 235th, 236th, 267th, 268th, 299th positions of the Fc domain of the GL-2045 Storado body described in WO2012 / 016073 , 324th, 345th, 430th and 440th positions were mutated. The amino acid sequences of exemplary Stora polysomes are shown in Table 1 above.

[0266] For each Storado body generated, the levels of canonical FcγR binding, complement C1q binding, and CDC inhibition were determined and compared to the parental Storado body, GL-2045 (IgG1 hinge-IgG1CH2IgG1CH3-IgG2 hinge).

[0267]Binding of the common Storado or the parental Storado, GL-2045, to FcyRI, FcyRIIb, FcyRIIIa, FcyRIIa was assessed. Dissociated RU values ​​were measured by biolayer interferometry using a ForteBio...

example 2

[0276] Example 2 - Enhanced Complement Fixation by Common Storadobody

[0277] A study was performed to evaluate the binding of common Storados to C1q, the results of which are summarized in Table 3.

[0278] For C1q binding, 96-well plates were coated overnight with C1q (Sigma Cat#: C1740 1 μg / mL) in PBS. After coating, plates were washed 3 times with standard wash buffer (PBS + 0.05% Tween 20) and blocked with blocking buffer (1% BSA-0.05% PBS Tween) for 2 hours at room temperature. After blocking, plates were incubated with 100 μL / well of compound diluted in blocking buffer and washed 3 times with standard wash buffer. By incubating with 1:5000 biotinylated mouse anti-human IgG1 (Cat#555869, BD Biosciences) and streptavidin-HRP (Cat#:7100-05Southern Biotech) (100 μL / well) at room temperature After 1 hour, followed by 3 washes with wash buffer, C1q-bound compounds were developed for 15 minutes using the standard TMB method according to the manufacturer's protocol. Absor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
pore sizeaaaaaaaaaa
Login to View More

Abstract

The present invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly ordered multimeric fractions, termed stradomers. The invention involves fusion proteins that bind to Fc[gamma]Rs and complement and that are useful in the treatmentand prevention of disease.

Description

[0001] References to related applications [0002] This application claims priority to U.S. Provisional Application No. 62 / 365,921, filed July 22, 2016, and U.S. Provisional Application No. 62 / 365,919, filed July 22, 2016, the contents of which are incorporated herein by reference in their entirety. [0003] Description of Text Files Submitted Electronically [0004] The contents of the text file filed electronically with this article are hereby incorporated by reference in their entirety: Copy of Sequence Listing in Computer Readable Format (File Name: GLIK_019_01WO_SeqList_ST25.txt, Date of Record: July 24, 2017, File Size: 68K byte). technical field [0005] The present invention relates generally to the fields of immunology, autoimmunity, inflammation and tumor immunology. More specifically, the present invention relates to biologically active biomimetic molecules comprising naturally associated immunoglobulin Fc domains (which exhibit altered Fc receptor binding and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K45/06C07K14/47
CPCC07K16/00C07K2317/52C07K2317/72C07K2319/30C07K2319/70C07K2317/41C07K2317/524C07K2317/64C07K2317/732C07K2317/734C07K2317/53A61P13/12A61P17/00A61P19/02A61P21/00A61P21/04A61P25/00A61P25/16A61P25/18A61P25/28A61P27/02A61P27/16A61P29/00A61P37/00A61P37/02A61P37/06A61P37/08A61P5/14A61P7/00A61P7/06A61P9/00A61P9/10A61K2039/505C07K16/18
Inventor D.S.布洛克H.奥尔森
Owner GLIKNIK
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com